RESUMO
OBJECTIVE: To develop and validate a set of static and animated gastroduodenal symptom pictograms for children. STUDY DESIGN: There were 3 study phases: 1: cocreation using experience design methods to develop pediatric gastroduodenal symptom pictograms (static and animated); 2: an online survey to assess acceptability, as well as face and content validity; and 3: a preference study. Phases 2 and 3 compared the novel pediatric pictograms with existing pictograms used with adult patients. RESULTS: Eight children aged 6-15 years (5 female) participated in phase 1, and 69 children in phase 2 (median age 13 years: IQR 9-15); an additional 49 participants were included in phase 3 (median age 15: IQR 12-17). Face and content validity were higher for the pediatric static and animated pictogram sets compared with pre-existing adult pictograms (78% vs 78% vs 61%). Participants with worse gastric symptoms had superior comprehension of the pediatric pictograms (χ2 [8, N = 118] P < .001). All participants preferred the pediatric static pictogram set was over both the animated and adult sets (χ2 [2, N = 118] P < .001). CONCLUSIONS: The cocreation phase resulted in the symptom concept confirmation and design of 10 acceptable static and animated gastroduodenal pictograms with high face and content validity when evaluated with children aged 6-18. Validity was superior when children reported more problematic symptoms. Therefore, these pictograms could be used in clinical and research practice to enable standardized symptom reporting for children with gastroduodenal disorders.
Assuntos
Compreensão , Adulto , Humanos , Feminino , Criança , Adolescente , Inquéritos e QuestionáriosRESUMO
Upper gastrointestinal symptoms affect 10% of the population, leading to significant costs and negatively impacting quality of life. Diagnosing disorders such as functional dyspepsia and gastroparesis is challenging due to overlapping symptoms. Gastric emptying scintigraphy (GES) has reproducibility issues. Body Surface Gastric Mapping (BSGM) is an advanced technique for precise and reliable electrophysiological mapping, overcoming the limitations of electrogastrography (EGG). Gastric Alimetry® measures gastric myoelectric potentials, providing valuable diagnostic data. BSGM uses an electrode array to capture gastric activity and requires a standardized protocol for comparable data. The metrics generated help identify specific gastric dysfunction phenotypes, improving diagnostic accuracy. These advancements promise to revolutionize the clinical management of chronic gastric symptoms, making this review essential reading for those interested in gastrointestinal research and treatment.
Los síntomas gastroduodenales afectan a más del 10% de la población, causando costos significativos e impac- tando negativamente la calidad de vida. Diagnosticar trastornos como la dispepsia funcional y la gastroparesia es complejo debido a la superposición de síntomas. El cintigrama de vaciamiento gástrico (CVG) y electrogas- trografía (EGG) tiene problemas de reproducibilidad. El Mapeo de superficie de Cuerpo Gástrico (MSCG) o conocida también como Alimetría gástrica, es una técnica avanzada que permite un mapeo electrofisiológico preciso y fiable, superando las limitaciones de la EGG. La Alimetría Gástrica mide los potenciales mioeléc - tricos gástricos, proporcionando datos útiles para el diagnóstico. El MGSC utiliza una matriz de electrodos para capturar la actividad gástrica y requiere un protocolo estandarizado para obtener datos comparables. Las métricas generadas ayudan a identificar fenotipos específicos de disfunción gástrica, mejorando la precisión diagnóstica. Estos avances prometen revolucionar el manejo clínico de los síntomas gástricos crónicos, ha - ciendo de esta revisión una lectura esencial para aquellos interesados en la investigación y tratamiento de problemas gastrointestinales
Assuntos
Humanos , Mapeamento Potencial de Superfície Corporal/métodos , Técnicas de Diagnóstico do Sistema Digestório , Motilidade Gastrointestinal/fisiologiaRESUMO
Resumen Helicobacter pylori (H. pylori) es un bacilo gramnegativo microaerófilo, capaz de colonizar la mucosa gástrica. Este microorganismo infecta a más de la mitad de la población mundial, por lo que se ha convertido en la infección bacteriana más común. La prevalencia de la infección y de las enfermedades asociadas a ella es alta, sobre todo en países en vías de desarrollo. El tratamiento recomendado para la erradicación es la triple terapia; sin embargo, su eficacia ha disminuido por el desconocimiento del patrón de susceptibilidad bacteriano por parte del personal médico y dada la aparición de cepas resistentes. La resistencia en H. pylori se asocia con la capacidad de adaptación de la bacteria a ambientes hostiles y al uso de los antibióticos. En Colombia, existen reportes acerca de que H. pylori presenta resistencia a amoxicilina, metronidazol, claritromicina, furazolidona, levofloxacina y tetraciclina. Los estudios del patrón de susceptibilidad determinaron que la frecuencia de resistencia de H. pylori es variable y demuestran la falta de datos en la mayoría del territorio del país. Sobre la base de lo anterior, el objetivo de esta revisión es describir los porcentajes de resistencia de H. pylori a los antibióticos amoxicilina, metronidazol, claritromicina, furazolidona, levofloxacina y tetraciclina, usados en el tratamiento de la infección en los estudios realizados en Colombia.
Abstract Helicobacter pylori (H. pylori) is a microaerophilic gram-negative bacillus that colonizes the gastric mucosa. It infects more than half the world's population, making it the most common bacterial infection. The prevalence of infection and associated diseases is high in developing countries. The recommended treatment for its eradication is triple therapy; however, its efficacy has decreased due to the lack of knowledge of the bacterial susceptibility pattern among the medical staff and the emergence of resistant strains. H. pylori susceptibility is associated with the bacteria's ability to adapt to hostile environments and the use of antibiotics. In Colombia, it has been reported that H. pylori is resistant to amoxicillin, metronidazole, clarithromycin, furazolidone, levofloxacin, and tetracycline. Studies on the susceptibility pattern have determined that the frequency of H. pylori susceptibility is variable and demonstrate the lack of data in most of the Colombian territory. With this in mind, the objective of this review is to describe the percentage of resistance to amoxicillin, metronidazole, clarithromycin, furazolidone, levofloxacin and tetracycline, which are used for the treatment of H. pylori infection, according to studies conducted in Colombia.